Molbio Diagnostics Invests $30 Million in OptraSCAN to Revolutionize Digital Pathology

BioNTech Acquires Chinese Oncology Firm Biotheus for $950M

The Care and Protection of Children Trust

CPCT Launches Groundbreaking Initiative to Provide Lifelong Free Treatment for Children with Spinal Muscular Atrophy (SMA) in Karnataka

Early Comprehensive Genomic Profiling Improves Cancer Treatment Outcomes, Study Shows

EMA Reverses Decision, Recommends Limited Approval for Eisai and Biogen’s Alzheimer’s Drug Leqembi

Exact Sciences Unveils Advances in Multi-Cancer Early Detection with Cancerguard™ Test

MSD and LaNova Medicines Enter Exclusive Global License Agreement for Novel Cancer Therapy, LM-299

Promising CAR T Cell Therapies from BMS and Cabaletta Bio Show Potential for Durable Remission in Severe Lupus

FDA Grants Accelerated Approval to PTC Therapeutics' KEBILIDI™, the First Gene Therapy for AADC Deficiency in the U.S.

Association for Molecular Pathology Publishes Joint Consensus Report on SARS-CoV-2 Genomic Surveillance for Hospitals and Public Health Laboratories

Philips India Unveils Advanced Azurion Imaging System to Revolutionize Cardiac and Neurovascular Care

Tempus AI Study Highlights Benefits of Dual RNA and DNA Sequencing for Advanced Lung Cancer

Ontada and Datavant Partner to Expand Access to Real-World Oncology Data for Accelerated Cancer Innovation

Tempus AI and Flatiron Health Partner to Integrate Genomic Testing into OncoEMR for Enhanced Oncology Care

Flare Therapeutics and Roche Forge Strategic Partnership to Discover Precision Oncology Therapies Targeting Transcription Factors

Home
/
update
/
details

FDA Approves Servier's Voranigo for IDH-Mutated Gliomas

NextEdge Admin

09 Aug 2024

1 min 46 sec

The US Food and Drug Administration has approved Servier Pharmaceuticals' Voranigo (vorasidenib) as a treatment for patients with IDH1- or IDH2-mutated grade 2 astrocytoma or oligodendroglioma. This approval is for both adult and pediatric patients older than 12 who have previously undergone surgical interventions, such as biopsy, subtotal resection, or gross total resection. Voranigo's approval is grounded in the positive outcomes of the Phase III INDIGO clinical trial, where patients with IDH1/2-mutated residual or recurrent grade 2 glioma who were treated with Voranigo showed a significant improvement in survival. They lived a median of 27.7 months compared to 11.1 months for those who received a placebo. The INDIGO trial involved 331 patients, and the determination of IDH1/2 mutation status in tumors was performed using Thermo Fisher Scientific's next-generation sequencing test, Oncomine Dx.

Voranigo is the latest addition to Servier's growing portfolio of IDH enzyme inhibitors. The company also markets Idhifa (enasidenib), which is approved for the treatment of advanced IDH2-mutant acute myeloid leukemia, and Tibsovo (ivosidenib), approved for patients with IDH1-mutated acute myeloid leukemia and IDH1-mutated cholangiocarcinoma.